199 related articles for article (PubMed ID: 24623139)
1. Protein quantity on the air-solid interface determines degradation rates of human growth hormone in lyophilized samples.
Xu Y; Grobelny P; Von Allmen A; Knudson K; Pikal M; Carpenter JF; Randolph TW
J Pharm Sci; 2014 May; 103(5):1356-66. PubMed ID: 24623139
[TBL] [Abstract][Full Text] [Related]
2. Storage stability of keratinocyte growth factor-2 in lyophilized formulations: effects of formulation physical properties and protein fraction at the solid-air interface.
Devineni D; Gonschorek C; Cicerone MT; Xu Y; Carpenter JF; Randolph TW
Eur J Pharm Biopharm; 2014 Oct; 88(2):332-41. PubMed ID: 24859390
[TBL] [Abstract][Full Text] [Related]
3. Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-gamma.
Webb SD; Cleland JL; Carpenter JF; Randolph TW
J Pharm Sci; 2003 Apr; 92(4):715-29. PubMed ID: 12661058
[TBL] [Abstract][Full Text] [Related]
4. Thiol-disulfide exchange in peptides derived from human growth hormone during lyophilization and storage in the solid state.
Chandrasekhar S; Topp EM
J Pharm Sci; 2015 Apr; 104(4):1291-302. PubMed ID: 25631887
[TBL] [Abstract][Full Text] [Related]
5. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres.
Cleland JL; Jones AJ
Pharm Res; 1996 Oct; 13(10):1464-75. PubMed ID: 8899836
[TBL] [Abstract][Full Text] [Related]
6. Surface denaturation at solid-void interface--a possible pathway by which opalescent particulates form during the storage of lyophilized tissue-type plasminogen activator at high temperatures.
Hsu CC; Nguyen HM; Yeung DA; Brooks DA; Koe GS; Bewley TA; Pearlman R
Pharm Res; 1995 Jan; 12(1):69-77. PubMed ID: 7724490
[TBL] [Abstract][Full Text] [Related]
7. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.
Hassett KJ; Cousins MC; Rabia LA; Chadwick CM; O'Hara JM; Nandi P; Brey RN; Mantis NJ; Carpenter JF; Randolph TW
Eur J Pharm Biopharm; 2013 Oct; 85(2):279-86. PubMed ID: 23583494
[TBL] [Abstract][Full Text] [Related]
9. Optimization of storage stability of lyophilized actin using combinations of disaccharides and dextran.
Allison SD; Manning MC; Randolph TW; Middleton K; Davis A; Carpenter JF
J Pharm Sci; 2000 Feb; 89(2):199-214. PubMed ID: 10688749
[TBL] [Abstract][Full Text] [Related]
10. Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents.
Jalalipour M; Gilani K; Tajerzadeh H; Najafabadi AR; Barghi M
Int J Pharm; 2008 Mar; 352(1-2):209-16. PubMed ID: 18164150
[TBL] [Abstract][Full Text] [Related]
11. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
[TBL] [Abstract][Full Text] [Related]
12. Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: glass transition and protein conformation.
Chang BS; Beauvais RM; Dong A; Carpenter JF
Arch Biochem Biophys; 1996 Jul; 331(2):249-58. PubMed ID: 8660705
[TBL] [Abstract][Full Text] [Related]
13. Investigation of PEG crystallization in frozen and freeze-dried PEGylated recombinant human growth hormone-sucrose systems: implications on storage stability.
Bhatnagar BS; Martin SWH; Hodge TS; Das TK; Joseph L; Teagarden DL; Shalaev EY; Suryanarayanan R
J Pharm Sci; 2011 Aug; 100(8):3062-3075. PubMed ID: 21491456
[TBL] [Abstract][Full Text] [Related]
14. Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations.
Webb SD; Golledge SL; Cleland JL; Carpenter JF; Randolph TW
J Pharm Sci; 2002 Jun; 91(6):1474-87. PubMed ID: 12115847
[TBL] [Abstract][Full Text] [Related]
15. Instability of therapeutic proteins - An overview of stresses, stabilization mechanisms and analytical techniques involved in lyophilized proteins.
Butreddy A; Janga KY; Ajjarapu S; Sarabu S; Dudhipala N
Int J Biol Macromol; 2021 Jan; 167():309-325. PubMed ID: 33275971
[TBL] [Abstract][Full Text] [Related]
16. Stability of lyophilized human growth hormone.
Salnikova MS; Middaugh CR; Rytting JH
Int J Pharm; 2008 Jun; 358(1-2):108-13. PubMed ID: 18394830
[TBL] [Abstract][Full Text] [Related]
17. On the structural preservation of recombinant human growth hormone in a dried film of a synthetic biodegradable polymer.
Carrasquillo KG; Costantino HR; Cordero RA; Hsu CC; Griebenow K
J Pharm Sci; 1999 Feb; 88(2):166-73. PubMed ID: 9950633
[TBL] [Abstract][Full Text] [Related]
18. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the Formulation and Lyophilization Process for a Fragment Antigen Binding (Fab) Protein Using Solid-State Hydrogen-Deuterium Exchange Mass Spectrometry (ssHDX-MS).
Kumar L; Chandrababu KB; Balakrishnan SM; Allmendinger A; Walters B; Zarraga IE; Chang DP; Nayak P; Topp EM
Mol Pharm; 2019 Nov; 16(11):4485-4495. PubMed ID: 31568722
[TBL] [Abstract][Full Text] [Related]
20. Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone.
Costantino HR; Carrasquillo KG; Cordero RA; Mumenthaler M; Hsu CC; Griebenow K
J Pharm Sci; 1998 Nov; 87(11):1412-20. PubMed ID: 9811499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
